Compass Pathways has received a Rolling Review and a Conditional New Product Vouchers (CNPV) designation from the FDA for its treatment targeting Treatment-Resistant Depression (TRD).

Analysts are bullish on several biotech companies, including GH Research, Cybin D/B/A Helus Pharma, and COMPASS Pathways, following a psychedelics symposium and positive model updates, with Baird lowering Bright Minds Biosciences' price target but maintaining an Outperform rating.

Compass Pathways stock experienced a significant surge after former President Trump expressed support for psychedelics.

This article highlights the biggest stock movers on Tuesday, including ZIM and CMPS, indicating significant market activity for these companies.

An upcoming FDA review meeting will determine the future of Compass Pathways' depression drug candidate COMP360, as the company awaits regulatory feedback on its potential treatment.